{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:15:59Z","timestamp":1791288959714,"version":"4.3.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>Phenylketonuria (PKU) is an inborn error of metabolism caused by a deficiency in functional phenylalanine hydroxylase (PAH), resulting in accumulation of phenylalanine (Phe) in patients\u2019 blood and organs. Affected patients encounter severe developmental delay, neurological deficits, and behavioral abnormalities when not treated. Early diagnosis and treatment are extremely important; newborn screening programs have been implemented in most countries to ensure early identification of patients with PKU. Despite available treatment options, several challenges remain: life-long adherence to a strict diet, approval of some medications for adults only, and lack of response to these therapies in a subpopulation of patients. Therefore, there is an urgent need for treatment alternatives. An mRNA-based approach tested in PKU mice showed a fast reduction in the accumulation of Phe in serum, liver and brain, the most significant organ affected. Repeated injections of LNP-formulated mouse PAH mRNA rescued PKU mice from the disease phenotype for a prolonged period of time. An mRNA-based approach could improve the quality of life tremendously in PKU patients of all ages by replacing standard-of-care treatments.<\/jats:p>","DOI":"10.3389\/fbioe.2022.993298","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T06:04:30Z","timestamp":1665122670000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice"],"prefix":"10.3389","volume":"10","author":[{"given":"Maximiliano L.","family":"Cacicedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Weinl-Tenbruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Limeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wirsching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Hilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansure Abdollah","family":"Pasha Famian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Horscroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Hennermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Zepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Chevessier-T\u00fcnnesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Gehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"B2","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.omtm.2020.03.009","article-title":"Sustained correction of a murine model of phenylketonuria following a single intravenous administration of AAVHSC15-PAH","volume":"17","author":"Ahmed","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/psp4.12301","article-title":"Quantitative systems pharmacology model of hUGT1A1-modRNA encoding for the UGT1A1 enzyme to treat crigler-najjar syndrome type 1","volume":"7","author":"Apgar","year":"2018","journal-title":"CPT. Pharmacometrics Syst. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/B:BOLI.0000028725.37345.62","article-title":"Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria","volume":"27","author":"Arnold","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/archpedi.1991.02160010037012","article-title":"Intellectual development in 12-year-old children treated for phenylketonuria","volume":"145","author":"Azen","year":"1991","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"B8","first-page":"1417","article-title":"Phenylketonuria","volume-title":"The lancet","author":"Blau","year":"2010"},{"key":"B9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1126\/scitranslmed.abl9238","article-title":"In vivo prime editing of a metabolic liver disease in mice","volume":"14","author":"B\u00f6ck","year":"2022","journal-title":"Sci Transl Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.omtm.2022.07.006","article-title":"mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model","volume":"26","author":"Cacicedo","year":"2022","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/nejmoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3390\/nu12072154","article-title":"Bone status in patients with phenylketonuria: A systematic review","volume":"12","author":"de Castro","year":"2020","journal-title":"Nutrients"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-76698-8_5","article-title":"Amino acids","volume-title":"Laboratory guide to the methods in biochemical genetics","author":"Duran","year":"2008"},{"key":"B14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/iub.1150","article-title":"Phenylalanine hydroxylase: Function, structure, and regulation","volume":"65","author":"Flydal","year":"2013","journal-title":"IUBMB Life"},{"key":"B15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-021-04231-6","article-title":"Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine","volume":"601","author":"Gebre","year":"2022","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"30686","DOI":"10.1074\/jbc.M110.124016","article-title":"Activation of phenylalanine hydroxylase induces positive cooperativity toward the natural cofactor","volume":"285","author":"Gersting","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1089\/hum.2019.111","article-title":"State-of-the-Art 2019 on gene therapy for phenylketonuria","volume":"30","author":"Grisch-Chan","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ebiom.2018.10.038","article-title":"Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials","volume":"37","author":"Gupta","year":"2018","journal-title":"EBioMedicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"675897","DOI":"10.3389\/fimmu.2021.675897","article-title":"Challenges posed by immune responses to AAV vectors: Addressing root causes","volume":"12","author":"Hamilton","year":"2021","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.omtm.2019.10.011","article-title":"mRNA as a novel treatment strategy for hereditary spastic paraplegia type 5","volume":"15","author":"Hauser","year":"2019","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10545-012-9548-0","article-title":"Chronic kidney disease in adolescent and adult patients with phenylketonuria","volume":"36","author":"Hennermann","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ajhg.2020.06.006","article-title":"The genetic landscape and epidemiology of phenylketonuria","volume":"107","author":"Hillert","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1038\/s41467-020-19156-3","article-title":"Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat. Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/jimd.12392","article-title":"Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model","volume":"44","author":"Kaiser","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"B25","unstructured":"Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study6\n            KeilS.\n            AnjemaK.\n            van SpronsenF. J.\n            LambruschiniN.\n            BurlinaA.\n            B\u00e9langer-QuintanaA.\n          10.1002\/jimd.12392Pediatrics1312013"},{"key":"B26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: Advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/vaccines9040390","article-title":"Mrna-based vaccines","volume":"9","author":"Kowalzik","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/s1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in europe and Latin America (HERALD): A randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nn.2467","article-title":"A robust and high-throughput Cre reporting and characterization system for the whole mouse brain","volume":"13","author":"Madisen","year":"2010","journal-title":"Nat. Neurosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-017-0600-x","article-title":"Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial","volume":"12","author":"Muntau","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtn.2022.02.020","article-title":"Development of an mRNA replacement therapy for phenylketonuria","volume":"28","author":"Perez-Garcia","year":"2022","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ymgme.2005.04.008","article-title":"The activity of wild-type and mutant phenylalanine hydroxylase and its regulation by phenylalanine and tetrahydrobiopterin at physiological and pathological concentrations: An isothermal titration calorimetry study","volume":"86","author":"Pey","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e399","DOI":"10.1212\/WNL.0000000000011088","article-title":"Phenylalanine effects on brain function in adult phenylketonuria","volume":"96","author":"Pilotto","year":"2021","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/nejmoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"B35","doi-asserted-by":"publisher","first-page":"100855","DOI":"10.1016\/j.ymgmr.2022.100855","article-title":"Starting the conversation on gene therapy for phenylketonuria: Current perspectives of patients, caregivers, and advocates","volume":"31","author":"Regier","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.omtm.2019.12.004","article-title":"AAV-mediated CRISPR\/Cas9 gene editing in murine phenylketonuria","volume":"17","author":"Richards","year":"2020","journal-title":"Mol. Ther. - Methods & Clin. Dev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.ymthe.2018.01.006","article-title":"G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a","volume":"26","author":"Roseman","year":"2018","journal-title":"Mol. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"100603","DOI":"10.1016\/j.ymgmr.2020.100603","article-title":"First 1.5 years of pegvaliase clinic: Experiences and outcomes","volume":"24","author":"Sacharow","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B40","unstructured":"Mouse models of human phenylketonuria\n            ShedlovskyA.\n            McdonaldJ. D.\n            SymulaD.\n            DoveW. F.\n          1993"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/hmg\/ddr165","article-title":"The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response","volume":"20","author":"Staudigl","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","article-title":"Phenylketonuria","volume":"7","author":"van Spronsen","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2021.02.008","article-title":"Effect of BH4 on blood phenylalanine and tyrosine variations in patients with phenylketonuria","volume":"133","author":"van Wegberg","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.jhep.2020.12.010","article-title":"Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB\/c.Abcb4-\/- mouse model of PFIC3","volume":"74","author":"Wei","year":"2021","journal-title":"J. Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of fabry disease: Preclinical studies in wild-type mice, fabry mouse model, and wild-type non-human primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2022.993298\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T06:04:36Z","timestamp":1665122676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2022.993298\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":45,"alternative-id":["10.3389\/fbioe.2022.993298"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2022.993298","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"article-number":"993298"}}